RICHLAND, WA-- Aug 13, 2013 - IsoRay Inc. (NYSE MKT: ISR) (NYSE Amex: ISR) (www.isoray.com), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a booth at the 55th Annual Meeting of the American Society for Radiation Oncology (ASTRO). The annual meeting will take place September 22-24, 2013 in Atlanta, Georgia at the Georgia World Congress Center, and a number of papers are scheduled to be presented at the annual meeting on results achieved using IsoRay's products.
According to IsoRay CEO Dwight Babcock, "IsoRay now has more sales representatives speaking to the benefits of brachytherapy and presenting our products at new venues. We are seeing increased inquiries from the medical community about IsoRay's Cesium-131 (Cs-131) seeds, seed sutured mesh and GliaSite® for the treatment of a wide array of cancers throughout the body including brain, lung, ocular, gynecologic and prostate cancers. Our products offer an important advance over previous brain, head and neck, lung, prostate, abdominal wall and gynecological cancer treatments. With a number of papers being presented at ASTRO, we are encouraged as all of them showed very positive results realized in treating metastasized brain cancers, lung cancer and prostate cancer using Cs-131 or GliaSite®. Medical thought leaders recognize the need for a new powerful weapon in the battle against cancer and we believe Cesium-131 is that solution."
IsoRay has participated over the last quarter in the following industry shows, expanding its product awareness to differing specialists while sharing the benefits of Cesium-131 in their efforts to fight cancer:
1. American Brachytherapy Society (ABS) in New Orleans
2. American Association for Thoracic Surgery (AATS) in Minneapolis, Minnesota
3. American Association of Physicists in Medicine (AAPM) in Indianapolis, Indiana
IsoRay is also pleased to announce that Brigham and Women's (an affiliate of Harvard) and University Medical Center of Princeton have both recently begun treating patients using IsoRay products. Brigham and Women's has treated brain cancer and University Medical Center of Princeton has begun treating prostate cancer.
IsoRay's Cesium-131 sutured seeds, stranded mesh and the GliaSite® radiation therapy system each give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after completion of brain tumor removal. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy brain and lung tissue as well as critical structures compared to other alternative treatments. IsoRay's cancer fighting products reduce the ability of the tumor to recur, which means important benefits for patients in longevity as well as quality of life.
IsoRay is the exclusive manufacturer of Cesium-131. Cesium-131 is the first new isotope to be available in seed form for brachytherapy in approximately 20 years. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).
In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer, lung cancer, ocular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh, and several new implantable devices. IsoRay also distributes the GliaSite® radiation therapy system, used to treat brain cancers.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite® and Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray (http://www.facebook.com/#/IsoRay). Follow us on Twitter @Isoray (https://twitter.com/#!/Isoray).
Safe Harbor Statement
Statements in this news release about IsoRay's future expectations, including: the advantages of our Cesium-131 seed and its various delivery formats, the advantages of the Gliasite® delivery system, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether the use of GliaSite® or Cesium-131 will increase or continue, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of early clinical studies, patient results achieved with Cesium-131 or the Gliasite® delivery system, successful completion of future research and development activities, our ability to receive and maintain all required regulatory approvals in the U.S. and internationally, continued compliance with ISO standards as audited by BSI, and other risks detailed from time to time in IsoRay's reports filed with the SEC.